The study, commissioned by the Bertelsmann Foundation, found that nearly one-third of inventions developed in Germany are now owned by foreign organizations. U.S. entities hold the largest share, while Chinese owners account for a significant portion of foreign-held German patents.

The trend is particularly evident in Germany’s mechanical engineering sector, where patent applications increased to 4,300 in 2022 from 3,300 in 2000. Researchers said Chinese companies have been especially active in acquiring technologies linked to the industry.

IW expert Oliver Koppel said international ownership of patents is a normal feature of global competition but argued that China pursues acquisitions strategically while maintaining relatively limited access for foreign investors in its domestic market.

The study also highlighted concerns about Germany’s declining innovation capacity. Germany ranked third globally in research and development spending in 2000, when its investment levels were roughly double those of China. By 2021, Germany had fallen to sixth place, while China’s research spending had increased twentyfold over the same period.

The findings are likely to intensify debate in Europe over technological sovereignty, foreign investment screening and the protection of critical industrial know-how.

Novo Nordisk’s global transformation plan, including the restructuring of its workforce, is nearly complete, signaling the company’s focus on innovation, agility, and sustained leadership in the global healthcare and diabetes market.

Novo Nordisk has nearly completed its global restructuring initiative, which included job adjustments impacting approximately 9,000 employees across multiple regions.

The process, which CEO Mike Doustdar described as progressing smoothly, marks a pivotal phase in the company’s journey toward strengthening operational efficiency and maintaining its leadership in the competitive global pharmaceutical market.

Despite being a difficult transition, the restructuring demonstrates Novo Nordisk’s commitment to long-term stability, innovation, and sustainable growth.

In his recent LinkedIn post, Doustdar shared that the company has already notified employees affected by the restructuring in most locations.

The timeline and process varied depending on local regulations and employment laws, reflecting Novo Nordisk’s respect for regional labor standards and ethical corporate governance.

This thoughtful and transparent approach underscores the company’s dedication to handling workforce transitions with empathy, fairness, and professionalism while ensuring business continuity and focus on patient outcomes.

The restructuring comes at a time when Novo Nordisk faces growing competition in the United States, the world’s largest pharmaceutical market, especially from rival Eli Lilly.

Both companies have been at the forefront of developing innovative treatments for diabetes, obesity, and metabolic disorders.

With this new organizational structure, Novo Nordisk aims to enhance agility, strengthen its global supply chain, and allocate resources more effectively to areas driving the greatest patient impact.

While the announcement of job reductions may seem challenging, it reflects a forward-looking vision to optimize operations and improve efficiency.

Industry analysts view the move as a proactive strategy to streamline operations and adapt to evolving global market dynamics.

By reshaping its structure, Novo Nordisk is positioning itself to respond more effectively to the rising demand for its breakthrough therapies, including those targeting diabetes and obesity, two of the most pressing health challenges worldwide.

Novo Nordisk’s commitment to its mission of improving lives remains unchanged. The company continues to invest heavily in research and development, focusing on next-generation treatments and advanced biotechnologies.

Its state-of-the-art manufacturing facilities, including the one in Kalundborg, Denmark, play a vital role in maintaining product quality and meeting global demand.

The restructuring also aims to bolster these efforts by making the organization more flexible and responsive to emerging healthcare needs.

CEO Mike Doustdar emphasized that while such transitions are never easy, they are sometimes necessary for long-term growth and sustainability.

He expressed gratitude to all employees for their dedication, professionalism, and resilience during the restructuring period.

The CEO’s communication reflects Novo Nordisk’s people-first culture, recognizing the contributions of its workforce while preparing the company for a future defined by innovation and patient-centered care.

Experts believe that this transformation will help Novo Nordisk maintain its leadership position in the global market, particularly as demand for diabetes and obesity medications continues to soar.

The company’s focus on digital transformation, scientific excellence, and sustainable production practices further strengthens its reputation as a responsible and future-ready healthcare leader.

As the restructuring concludes, Novo Nordisk is expected to emerge stronger, leaner, and better equipped to drive growth in key therapeutic areas.

Novo Nordisk’s strategic evolution highlights its adaptability and vision in a rapidly changing healthcare landscape.

With innovation at its core and an unwavering focus on improving health outcomes, the company is set to continue delivering breakthrough solutions that address global health challenges.

This period of transformation is not a setback but rather a stepping stone toward a more efficient, dynamic, and forward-thinking future for Novo Nordisk and the millions of patients it serves worldwide.